Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors.
作者： Ryszard Smolarczyk , Tomasz Cichoń , Ewelina Pilny , Magdalena Jarosz-Biej , Aleksandra Poczkaj
DOI: 10.1038/S41598-018-25688-Y
关键词: Cytotoxic T cell 、 Melanoma 、 Transcription factor 、 Combination therapy 、 Cancer research 、 Hypoxia (medical) 、 Immune system 、 Chemistry 、 CD8 、 Mechanism of action
摘要: Vascular disrupting agents as DMXAA inhibit tumor growth only for a short period of time followed by rapid regrowth. Among others, hypoxia and presence transcription factor HIF-1α are responsible tumors The aim our study was to investigate the inhibition murine melanoma combining two agents: anti-vascular - inhibitor digoxin explaining mechanism action this combination. After treatment size reduced limited time. 7 days regrowth observed number vessels increased especially in tumor’s peripheral areas. also induced an influx immune cells: macrophages, CD8+ cytotoxic lymphocytes, NK cells, CD4+ lymphocytes. Administration alone inhibited tumors. both proper sequence significantly better than either alone. Combination therapy newly formed vessels. In mice treated with combination therapy, macrophages M1, cells lesser extent increased. inhibitors appears be effective therapeutic option.
harvard.edu
nature.com
paperity.org参考文章(30)
Georgina N. Masoud, Wei Li, HIF-1α pathway: role, regulation and intervention for cancer therapy Acta Pharmaceutica Sinica B. ,vol. 5, pp. 378- 389 ,(2015) , 10.1016/J.APSB.2015.05.007
Leticia Corrales, Laura Hix Glickman, Sarah M. McWhirter, David B. Kanne, Kelsey E. Sivick, George E. Katibah, Seng-Ryong Woo, Edward Lemmens, Tamara Banda, Justin J. Leong, Ken Metchette, Thomas W. Dubensky, Thomas F. Gajewski, Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity Cell Reports. ,vol. 11, pp. 1018- 1030 ,(2015) , 10.1016/J.CELREP.2015.04.031
Magdalena Jarosz-Biej, Ryszard Smolarczyk, Tomasz Cichoń, Natalia Kułach, Justyna Czapla, Sybilla Matuszczak, Stanisław Szala, Combined Tumor Cell-Based Vaccination and Interleukin-12 Gene Therapy Polarizes the Tumor Microenvironment in Mice. Archivum Immunologiae Et Therapiae Experimentalis. ,vol. 63, pp. 451- 464 ,(2015) , 10.1007/S00005-015-0337-Y
Do-Youn Oh, Tae-Min Kim, Sae-Won Han, Dong-Yeop Shin, Yun Gyoo Lee, Keun-Wook Lee, Jee Hyun Kim, Tae-You Kim, In-Jin Jang, Jong-Seok Lee, Yung-Jue Bang, Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors. Cancer Research and Treatment. ,vol. 48, pp. 28- 36 ,(2015) , 10.4143/CRT.2014.258
Pu Gao, Thomas Zillinger, Weiyi Wang, Manuel Ascano, Peihong Dai, Gunther Hartmann, Thomas Tuschl, Liang Deng, Winfried Barchet, Dinshaw J. Patel, Binding-Pocket and Lid-Region Substitutions Render Human STING Sensitive to the Species-Specific Drug DMXAA Cell Reports. ,vol. 8, pp. 1668- 1676 ,(2014) , 10.1016/J.CELREP.2014.08.010
Charlene M. Downey, Mehrnoosh Aghaei, Reto A. Schwendener, Frank R. Jirik, DMXAA Causes Tumor Site-Specific Vascular Disruption in Murine Non-Small Cell Lung Cancer, and like the Endogenous Non-Canonical Cyclic Dinucleotide STING Agonist, 2′3′-cGAMP, Induces M2 Macrophage Repolarization PLoS ONE. ,vol. 9, pp. e99988- ,(2014) , 10.1371/JOURNAL.PONE.0099988
Sujeong Kim, Lingyin Li, Zoltan Maliga, Qian Yin, Hao Wu, Timothy J. Mitchison, Anticancer flavonoids are mouse-selective STING agonists. ACS Chemical Biology. ,vol. 8, pp. 1396- 1401 ,(2013) , 10.1021/CB400264N
Sujeong Kim, Leonid Peshkin, Timothy J. Mitchison, Vascular disrupting agent drug classes differ in effects on the cytoskeleton. PLOS ONE. ,vol. 7, pp. 40177- ,(2012) , 10.1371/JOURNAL.PONE.0040177
Z G Fridlender, A Jassar, I Mishalian, L-CS Wang, V Kapoor, G Cheng, J Sun, S Singhal, L Levy, S M Albelda, Using macrophage activation to augment immunotherapy of established tumours British Journal of Cancer. ,vol. 108, pp. 1288- 1297 ,(2013) , 10.1038/BJC.2013.93
Asis Palazon, Ananda W. Goldrath, Victor Nizet, Randall S. Johnson, HIF Transcription Factors, Inflammation, and Immunity Immunity. ,vol. 41, pp. 518- 528 ,(2014) , 10.1016/J.IMMUNI.2014.09.008